Turn Downtime Into Cash!
He's showing regular people how they can make a killing as traders right from their homes!
Click here to see how.
Michael Robert Martin, insider at Aurinia Pharmaceuticals

Michael Robert Martin Insider Information

Michael R. Martin serves as Chief Operating Officer of the Company. Michael Martin is currently COO of Aurinia Pharmaceuticals Inc. In this role he oversees all Business Development, Licensing and Partner Management activities along with overall management of the Company's intellectual property portfolio. Additionally, Michael is responsible for the executive leadership of Aurinia's ocular program. Michael was formerly CEO, director and co-founder of the privately held Aurinia Pharmaceuticals Inc., which merged in 2013 with the former Isotechnika Pharma Inc. Michael is a biotech/pharmaceutical executive with over 20 years of industry experience. Michael joined Aurinia from Vifor Pharma where he held the position of Director, Global Business Development & Licensing. Prior to Vifor, Michael was a key member of the business development team that saw Aspreva sold to Galenica for US$915M. Upon joining Aspreva in 2004, Michael initiated the strategic launch planning process for CellCept® in “less-common” autoimmune diseases. These included such indications as pemphigus vulgaris, myasthenia gravis, and lupus nephritis.

What is Michael Robert Martin's net worth?

The estimated net worth of Michael Robert Martin is at least $3.00 million as of September 7th, 2021. Mr. Martin owns 142,824 shares of Aurinia Pharmaceuticals stock worth more than $2,999,304 as of September 18th. This net worth evaluation does not reflect any other investments that Mr. Martin may own. Learn More.

How old is Michael Robert Martin?

Mr. Martin is currently 49 years old. There are 6 older executives and no younger executives at Aurinia Pharmaceuticals. The oldest executive at Aurinia Pharmaceuticals is Mr. Massimiliano Colao, Chief Commercial Officer, who is 56 years old. Learn More.

How do I contact Michael Robert Martin?

The corporate mailing address for Mr. Martin and other Aurinia Pharmaceuticals executives is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. Aurinia Pharmaceuticals can also be reached via email at [email protected].

Has Michael Robert Martin been buying or selling shares of Aurinia Pharmaceuticals?

In the last ninety days, Michael Robert Martin has sold $2,551,450.00 in shares of Aurinia Pharmaceuticals stock. Most recently, Michael Robert Martin sold 90,000 shares of the business's stock in a transaction on Tuesday, September 14th. The shares were sold at an average price of $21.19, for a transaction totalling $1,907,100.00.

Who are Aurinia Pharmaceuticals' active insiders?

Aurinia Pharmaceuticals' insider roster includes Matthew Donley (VP), Peter Greenleaf (CEO), Robert Huizinga (EVP), Jill Leversage (Director), Michael Martin (Insider), Joseph Miller (CFO), and Neil Solomons (Insider).

Are insiders buying or selling shares of Aurinia Pharmaceuticals?

In the last twelve months, Aurinia Pharmaceuticals insiders bought shares 6 times. They purchased a total of 20,625 shares worth mmore than $225,483.75. In the last twelve months, insiders at the biotechnology company sold shares 8 times. They sold a total of 167,500 shares worth mmore than $3,386,875.00. The most recent insider tranaction occured on September, 14th when Michael Robert Martin Insider bought 90,000 shares worth more than $1,907,100.00. Insiders at Aurinia Pharmaceuticals own 3.1 % of the company.

Information on this page was last updated on 9/14/2021.

Michael Robert Martin Insider Trading History at Aurinia Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/14/2021Sell90,000$21.19$1,907,100.00View SEC Filing Icon  
9/10/2021Sell25,000$19.80$495,000.00View SEC Filing Icon  
8/9/2021Sell5,000$16.01$80,050.00View SEC Filing Icon  
7/28/2021Sell5,000$13.86$69,300.00211,861View SEC Filing Icon  
6/22/2021Sell5,000$13.76$68,800.00216,861View SEC Filing Icon  
See Full Table

Michael Robert Martin Buying and Selling Activity at Aurinia Pharmaceuticals

This chart shows Michael Robert Martin's buying and selling at Aurinia Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Aurinia Pharmaceuticals Company Overview

Aurinia Pharmaceuticals logo
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Read More

Today's Range

Now: $21.00
Low: $19.25
High: $21.27

50 Day Range

MA: $15.07
Low: $10.93
High: $21.50

2 Week Range

Now: $21.00
Low: $9.72
High: $21.86


5,899,491 shs

Average Volume

4,148,397 shs

Market Capitalization

$2.70 billion

P/E Ratio


Dividend Yield



Turn Downtime Into Cash!
He's showing regular people how they can make a killing as traders right from their homes!
Click here to see how.